S1PR1 and Cryptococcal meningitis: Other opportunistic infections increasing with age can be cryptococcal meningitis and herpes encephalitis (fingolimod, natalizumab) (318, 319), mucocutaneous herpes infection [sphingosine-1-phosphate receptor modulators, natalizumab, alemtuzumab], and varicella-zoster reactivation [sphingosine-1-phosphate receptor modulators, dimethyl fumarate (320), natalizumab, cladribine, alemtuzumab, ocrelizumab], human papilloma virus (fingolimod), and Listeria meningitis (alemtuzumab) [reviewed by (310, 321)].